JS001+IMP4297 in Patients With Advanced Cancer
Condition(s):Advanced CancerLast Updated:September 21, 2022Withdrawn
Hide Studies Not Open or Pending
Condition(s):Advanced CancerLast Updated:September 21, 2022Withdrawn
Condition(s):Ewing’s SarcomaLast Updated:May 19, 2017Completed
Condition(s):Recurrent Small Cell Lung CarcinomaLast Updated:November 19, 2019Completed
Condition(s):Solid TumorsLast Updated:December 6, 2021Completed
Condition(s):Refractory Solid Tumors; Cancer TumorLast Updated:June 6, 2012Completed
Condition(s):Brain and Central Nervous System TumorsLast Updated:February 5, 2018Completed
Condition(s):Advanced Malignant Neoplasm; ATM Gene Mutation; BRCA1 Gene Mutation; BRCA2 Gene Mutation; Metastatic Malignant Neoplasm; PALB2 Gene Mutation; Recurrent Malignant Neoplasm; Refractory Malignant NeoplasmLast Updated:September 28, 2023Active, not recruiting
Condition(s):Small Cell Lung Cancer; Extra-Pulmonary Small Cell CarcinomasLast Updated:January 3, 2024Active, not recruiting
Condition(s):Ovarian Cancer; Ovarian NeoplasmLast Updated:October 30, 2023Terminated
Condition(s):BRCA1 Mutation; BRCA2 Mutation; Ovarian Cancer; Fallopian Tube Cancer; High Grade Serous CarcinomaLast Updated:October 12, 2023Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.